Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Candiolo – page 63

987 clinical trials in Candiolo, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Candiolo at a glance
987
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

987 trials in Candiolo

Open in trial search

Glomerulonephritis membranous

Not recruiting

Study on the Effectiveness and Safety of Obinutuzumab and Tacrolimus for Patients with Primary Membranous Nephropathy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:F. Hoffmann-La Roche AG

Thrombotic microangiopathy

Not recruiting

Study on Ravulizumab for Patients with Thrombotic Microangiopathy After Stem Cell Transplant

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ravulizumab
  • Sponsor:Alexion Pharmaceuticals Inc.

Malignant melanoma

Not recruiting

Study of Fianlimab and Cemiplimab for Patients with Untreated Advanced Melanoma

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

B-cell lymphoma

Not recruiting

Long-term Study of Zanubrutinib for Patients with B-cell Blood Cancer

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Zanubrutinib
  • Sponsor:BeOne Medicines AG

Non-small cell lung cancer stage III+5

Not recruiting

Study Comparing Ociperlimab and Tislelizumab with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ociperlimab
  • Sponsor:Beigene Ltd.

Lupus nephritis+1

Not recruiting

Study of Ravulizumab for Adults with Lupus Nephritis or IgA Nephropathy

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ravulizumab
  • Sponsor:Alexion Pharmaceuticals Inc.

Triple negative breast cancer

Not recruiting

Study of Datopotamab Deruxtecan and Durvalumab for Adults with Untreated Triple-Negative or Hormone Receptor-Low/HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Diffuse large B-cell lymphoma

Not recruiting

Study on the Safety of Tafasitamab and Lenalidomide for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Incyte Corp.

Glioblastoma

Not recruiting

Study on the Safety and Effectiveness of 2-Hydroxyoleic Acid and Temozolomide with Radiotherapy for Patients with Newly Diagnosed Glioblastoma

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Idroxioleic acid
  • Sponsor:Laminar Pharmaceuticals S.A.

Chronic kidney disease+1

Not recruiting

Study on Finerenone for Children with Chronic Kidney Disease and Proteinuria Using ACEI or ARB

Investigational
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Finerenone
  • Sponsor:Bayer AG

Myelofibrosis

Not recruiting

Study of Imetelstat Compared to Drug Combination for Treating Intermediate-2 or High-Risk Myelofibrosis in Patients Not Responding to JAK-Inhibitor Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Alkylating agents
  • Sponsor:Geron Corp.

Plasma cell myeloma+1

Not recruiting

Study Comparing Ciltacabtagene Autoleucel with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed and Lenalidomide-Refractory Multiple Myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Candiolo

What the registry says about research in the country

01 Hematologic Malignancies

Advanced research focusing on blood cancers including innovative treatments for myelodysplastic syndromes, follicular lymphoma, and chronic myelomonocytic leukemia. Studies evaluate novel drug combinations and maintenance therapies to improve patient outcomes.

  • Multiple Myeloma Treatment Optimization
  • Lymphoma Therapy Innovations
  • Leukemia Treatment Strategies

Trials investigate targeted therapies and immunotherapy approaches for better disease management.

02 Solid Tumors

Comprehensive research on lung cancer, breast cancer, and colorectal cancer. Studies explore combination therapies involving immunotherapy, targeted agents, and conventional treatments to enhance treatment efficacy.

  • Advanced NSCLC Treatments
  • Metastatic Disease Management
  • Novel Drug Combinations

Focus on personalized medicine approaches and biomarker-driven treatment selection.

03 Rare Cancers

Dedicated research into sarcomas, head and neck cancers, and other rare malignancies. Studies evaluate novel therapeutic approaches including immunotherapy combinations and targeted treatments.

  • Osteosarcoma Treatments
  • Soft Tissue Sarcoma Therapy
  • Innovative Treatment Protocols

Emphasis on developing effective treatments for cancers with limited therapeutic options.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.